Daiichi Sankyo has announced positive Phase 3 results for its Inavir laninamivir octanoate hydrate dry powder inhaler as a prophylactic antiviral. According to the company, the study found that Inavir produced statistically significant reductions in influenza infection compared to placebo among household members in contact with patients infected with influenza A or B, and the drug was well tolerated. Complete data will be published at a later date.
Based on the positive results, Daiichi Sankyo, says, it intends to submit a marketing application for a prophylactic indication for Inavir in Japan by the end of the year. The company launched the Inavir DPI in Japan for the treatment of influenza in October 2010.
Read the Daiichi Sankyo press release.
